Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Talphera will host a fireside chat and 1x1 investor meetings at the H.C. Wainwright conference, with live webcast and 90-day replay access.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talphera (TLPH)/b) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, at 4:30 p.m. ET in New York, NY.The session will feature a fireside chat and 1x1 meetings with CEO Vince Angotti and Chief Medical Officer Shakil Aslam, MD. A webcast and 90-day replay will be available via Talphera’s investor website.
Key Figures
- Conference Edition
- 28th annual
- H.C. Wainwright Global Investment Conference
- Presentation Date
- September 14, 2026 at 4:30pm ET
- H.C. Wainwright conference
- Meeting Format
- 1x1 meetings
- Alongside fireside chat
- Webcast Replay
- 90 days
- Following the event
Historical Context
-
Clinical enrollment progress and guideline support accompanied quarterly financial results.
-
Company scheduled its second-quarter results conference call and webcast.
-
Trial enrollment progress and a $4.1 million financing tranche were reported.
-
Company announced the release date for first-quarter financial results.
-
Two abstracts covering nafamostat and the NEPHRO-CRRT trial were accepted.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
H.C. Wainwright 28th Annual Global Investment Conference
Date: Monday, September 14, 2026 at 4:30pm ET
Location:
Presenter: Chief Executive Officer, Vince Angotti, and Chief Medical Officer, Shakil Aslam, MD
Format: Fireside Chat and 1x1 Meetings
Webcast Information
The webcast can be accessed here or by visiting the Talphera website on the News & Events section of the Investors page. A replay of the webcast will be available for 90 days following the event.
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-participate-in-the-hc-wainwright-28th-annual-global-investment-conference-302868347.html
SOURCE Talphera, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.